• Molecular NameLincomycin
  • SynonymLCM; Lincomycin hydrochloride; Lincomycine; Lincomyocin
  • Weight406.544
  • Drugbank_IDDB01627
  • ACS_NO154-21-2
  • Show 3D model
  • LogP (experiment)0.2
  • LogP (predicted, AB/LogP v2.0)0.44
  • pka7.5
  • LogD (pH=7, predicted)-0.18
  • Solubility (experiment)750 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.07
  • LogSw (predicted, AB/LogsW2.0)85.77
  • Sw (mg/ml) (predicted, ACD/Labs)12.54
  • No.of HBond Donors5
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds7
  • TPSA147.79
  • StatusFDA approved
  • AdministrationIM/IV
  • PharmacologyA lincosamide antibiotic that comes from the actinomyces Streptomyces lincolnensis.
  • Absorption_value28.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability25.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life5.4 h after IM or IV administration
  • Excretionrenal and biliary
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most frequently reported adverse events in the overall study population were transient decreased vision, fever, foreign body sensation, headache, transient ocular burning, ocular pain or discomfort, pharyngitis and photophobia. These events occurred in approximately 1-3% of patients. Other reported reactions occurring in less than 1% of patients included allergic reactions, lid edema, ocular dryness, and ocular itching.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A